Dublin-based Aerska, focused on RNA interference therapeutics for neurological diseases, raised $21 million in a seed financing round. The company’s antibody-oligonucleotide conjugate platform aims to enable gene silencing across the blood-brain barrier, tackling genetic forms of Alzheimer's and Parkinson's disease. Investors include Age1, Backed VC, Speedinvest, and others. Aerska intends to leverage this funding for preclinical validation and nomination of development candidates, targeting the critical unmet need in CNS genetic disorders.